Celgene Thalomid Multiple Myeloma sNDA Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene said that it will submit a completed study which compares thalidomide plus dexamethasone to dexamethasone alone in previously untreated patients, as well as additional data. Accelerated approval is possible in six to nine months, the company says.